Breaking News Instant updates and real-time market news.

NVS

Novartis

$82.21

-2.18 (-2.58%)

, ABBV

AbbVie

$90.77

-2.32 (-2.49%)

16:44
10/11/18
10/11
16:44
10/11/18
16:44

Novartis division Sandoz, AbbVie resolve IP related litigation for Hyrimoz

Sandoz, a Novartis (NVS) division, announced a global resolution of all intellectual property, or IP, related litigation with AbbVie (ABBV) concerning the proposed Sandoz biosimilar Hyrimoz for reference medicine Humira. Under the terms of the agreement, AbbVie grants Sandoz a non-exclusive license to AbbVie's intellectual property relating to Humira, beginning on certain dates in certain countries in which AbbVie has intellectual property. The license period will begin on October 16 in most countries in the European Union, and on other dates in various other countries outside the U.S. where AbbVie has IP. In the U.S., the license period will begin on September 30, 2023. Sandoz will pay royalties to AbbVie for licensing its Humira patents. All litigation pending between the parties will be dismissed. AbbVie will make no payments to Sandoz. The precise terms are confidential between the parties. Sandoz biosimilar adalimumab was recently approved by the European Commission for the 31 countries of the European economic area, which comprises the 28 member countries of the European Union plus Norway, Iceland and Liechtenstein.

NVS

Novartis

$82.21

-2.18 (-2.58%)

ABBV

AbbVie

$90.77

-2.32 (-2.49%)

  • 19

    Oct

  • 19

    Oct

  • 07

    Nov

NVS Novartis
$82.21

-2.18 (-2.58%)

09/17/18
FBCO
09/17/18
NO CHANGE
Target $26
FBCO
Neutral
Teva price target raised to $26 from $23 at Credit Suisse
Credit Suisse analyst Vamil Divan reiterated a Neutral rating on Teva Pharmaceutical (TEVA) and raised his price target to $26 after the company said it received FDA approval for Ajovy, a key pipeline drug for migraine prevention and approval of a quarterly dosing for the drug, providing an important point of differentiation relative to competitors from Eli Lilly (LLY) and Amgen (AMGN)/Novartis (NVS). In a research note to investors, Divan says Friday's approval provides Teva with an important potential growth driver as it looks to overcome the challenges it faces with U.S. generics, Copaxone and its large debt load, and expects a "strong" positive reaction in the stock. Divan says he will look to see how Teva commercializes Ajovy in the coming months before becoming more constructive on the stock's longer-term outlook.
09/19/18
PIPR
09/19/18
NO CHANGE
Target $50
PIPR
Overweight
Piper recommends Deciphera into systemic mastocytosis data
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on shares of Deciphera Pharmaceuticals (DCPH) with a $50 price target following a deep dive into the systemic mastocytosis treatment space and the potential for DCC-2618 to play a meaningful role in the disease. The analyst continues to recommend purchase of Deciphera into the systemic mastocytosis data for DCC-2618 early next year. Given what's been presented before between Novartis' (NVS) midostaurin and Blueprint Medicines' (BPMC) avapritinib, Raymond thinks an overall response rate of greater than 50% with a continued clean safety profile should be considered a win for DCC-2618. He models for DCC-2618 systemic mastocytosis revenue of $44M, $151M, and $290M for 2023 through 2025, respectively. The analyst remains a buyer of Deciphera shares into the Q1 of 2019 data.
09/28/18
WELS
09/28/18
NO CHANGE
WELS
Market Perform
Lilly's migraine treatment approval adds to Teva worries, says Wells Fargo
Wells Fargo analyst David Maris noted that Eli Lilly (LLY) received FDA approval of Emgality for the prevention of migraines and announced a U.S. list price of $6,900 annually, which is in line with Teva's (TEVA) Ajovy and Aimovig from Amgen (AMGN) and Novartis (NVS). Lilly's approval adds to Teva investor worries, said Maris, who sees migraines being a competitive market with similar drugs "where the competitors are marketing powerhouses...and Teva is undergoing a lot of organizational change." He maintains a Market Perform rating on Teva shares.
10/08/18
GUGG
10/08/18
INITIATION
GUGG
Neutral
Novartis initiated with a Neutral at Guggenheim
Guggenheim analyst Seamus Fernandez started Novartis with a Neutral rating and CHF 94 price target, stating that its Alcon spin likely will generate value, but he believes additional pipeline catalysts are needed to drive operating leverage.
ABBV AbbVie
$90.77

-2.32 (-2.49%)

09/19/18
PIPR
09/19/18
NO CHANGE
Target $100
PIPR
Neutral
Piper more worried about AbbVie co-pay accumulator risk than California suit
While shares of AbbVie may move lower today on news of California's insurance regulator suing the company over promotion of Humira, a more fundamental potential drag on Humira remains the advent of co-pay accumulators, Piper Jaffray analyst Christopher Raymond tells investors in a research note. The analyst sees the California lawsuit as more headline risk than anything but thinks "it may nevertheless serve as a minor overhang on shares." He points out that new research this week by Drug Channels suggests that more than one-third of commercial lives are enrolled in plans that have implemented copay accumulators for 2018, higher than his prior best estimate of 17%. Raymond keeps a Neutral rating on AbbVie with a $100 price target.
09/19/18
FBCO
09/19/18
NO CHANGE
Target $85
FBCO
Underperform
AbbVie's California lawsuit may have broader implications, says Credit Suisse
After the State of California has filed a lawsuit against AbbVie, accusing the company of paying kickbacks to doctors and using a network of nurses to illegally boost Humira prescriptions, Credit Suisse analyst Vamil Divan said he is "not surprised" by the stock's weakness given how leveraged it is to Humira sales and profit, and think there could be additional weakness as the story develops, especially if other states file similar lawsuits against the company. Additionally, he wonders how lawsuits like this may impact marketing practices across the industry. Divan maintains a cautious view on the stock with an Underperform rating and $85 price target, and says he continues to have concerns about the sustainability of Humira given the expected entry of multiple biosimilars in the EU next month expected biosimilar pressure in the U.S. starting in 2023.
09/19/18
MSCO
09/19/18
NO CHANGE
MSCO
Equal Weight
Morgan Stanley says AbbVie market cap fell more than largest drug settlement
After AbbVie (ABBV) slid about 3% yesterday following a California Insurance Commissioner lawsuit alleging Humira kickbacks, Morgan Stanley analyst David Risinger noted its $4B loss in market cap was larger than GlaxoSmithKline's (GSK) previous $3B settlement for violations under the False Claims Act, which he called the biggest ever historical pharma settlement. While Commissioner Dave Jones claims imply that the potential fine for Abbvie could theoretically be more than $3B, Risinger also noted that the company told him it believes the allegations "are completely without merit." He maintains an Equal Weight rating and $100 price target on AbbVie shares.
10/02/18
PIPR
10/02/18
NO CHANGE
Target $100
PIPR
Neutral
AbbVie scripts for Humira relatively weak in Q3, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond says new survey data from dermatologists and gastroenterologists indicate AbbVie's (ABBV) Humira is losing share faster in psoriasis and inflammatory bowel disease than in rheumatoid arthritis. In that management has called out psoriasis as a key driver of growth, the survey feedback may help explain Humira's relatively weak script trends for Q3, Raymond tells investors in a research note. The analyst believes dermatologists are embracing newer biologics such as Johnson & Johnson's (JNJ) Tremfya while gastroenterologists favor Takeda's Entyvio and increasingly Pfizer's (PFE) Xeljanz. Raymond remains cautious on shares of AbbVie ahead of European biosimilar erosion he expects to start this month. He keeps a Neutral rating on the stock with a $100 price target.

TODAY'S FREE FLY STORIES

RHHBY

Roche

$0.00

(0.00%)

, ONCE

Spark Therapeutics

$51.53

0.91 (1.80%)

15:26
02/23/19
02/23
15:26
02/23/19
15:26
Periodicals
Roche near deal to buy Spark Therapeutics for near $5B, WSJ says »

Roche Holding (RHHBY) is…

RHHBY

Roche

$0.00

(0.00%)

ONCE

Spark Therapeutics

$51.53

0.91 (1.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Mar

  • 05

    Mar

  • 11

    Mar

  • 18

    Mar

  • 04

    Apr

  • 19

    Aug

AAPL

Apple

$172.82

1.7 (0.99%)

, SSNLF

Samsung

$0.00

(0.00%)

12:41
02/23/19
02/23
12:41
02/23/19
12:41
Periodicals
Smartphone replacement cycle should help out sector in 2019, Barron's says »

With 3B smartphone…

AAPL

Apple

$172.82

1.7 (0.99%)

SSNLF

Samsung

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 01

    Mar

WIN

Windstream

$0.84

-0.1177 (-12.29%)

, UNIT

Uniti Group

$9.40

-0.58 (-5.81%)

12:33
02/23/19
02/23
12:33
02/23/19
12:33
Periodicals
Aurelius' triumph in court threatens Windstream viability, Barron's says »

Aurelius Capital's…

WIN

Windstream

$0.84

-0.1177 (-12.29%)

UNIT

Uniti Group

$9.40

-0.58 (-5.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 28

    Feb

  • 11

    Mar

WCG

WellCare

$276.24

1.74 (0.63%)

12:27
02/23/19
02/23
12:27
02/23/19
12:27
Periodicals
Healthy prospects should cure ailing WellCare stock, Barron's says »

Investors looking for a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

Nvidia

$159.45

3.69 (2.37%)

12:23
02/23/19
02/23
12:23
02/23/19
12:23
Periodicals
Gamers might have final say on Nvidia stock, Barron's says »

For a while, Nvidia was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

BF.A

Brown-Forman, also tag with BFA, BFB

$49.12

0.73 (1.51%)

, LVS

Las Vegas Sands

$61.50

-0.03 (-0.05%)

12:20
02/23/19
02/23
12:20
02/23/19
12:20
Periodicals
Altria paying big dividends, Barron's says »

Companies that traffic in…

BF.A

Brown-Forman, also tag with BFA, BFB

$49.12

0.73 (1.51%)

LVS

Las Vegas Sands

$61.50

-0.03 (-0.05%)

BF.B

Brown-Forman, also tag with BFA, BFB

$48.83

0.46 (0.95%)

BFA

Brown-Forman, also tag with BF.A, BF.B

$0.00

(0.00%)

BFB

Brown-Forman, also tag with BF.A, BF.B

$0.00

(0.00%)

MO

Altria Group

$51.50

1.12 (2.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

  • 06

    Mar

  • 28

    May

KLAC

KLA-Tencor

$114.50

1.55 (1.37%)

, LRCX

Lam Research

$179.00

0.17 (0.10%)

12:11
02/23/19
02/23
12:11
02/23/19
12:11
Periodicals
Cold War in tech should not be ignored, Barron's says »

While investors are…

KLAC

KLA-Tencor

$114.50

1.55 (1.37%)

LRCX

Lam Research

$179.00

0.17 (0.10%)

ADI

Analog Devices

$105.90

0.64 (0.61%)

NVDA

Nvidia

$159.45

3.69 (2.37%)

SWKS

Skyworks

$82.43

0.67 (0.82%)

XLNX

Xilinx

$122.97

3.77 (3.16%)

INTC

Intel

$52.58

1.18 (2.30%)

AMAT

Applied Materials

$39.40

0.56 (1.44%)

MXIM

Maxim Integrated

$55.88

0.65 (1.18%)

AMD

AMD

$24.40

0.48 (2.01%)

NXPI

NXP Semiconductors

$94.49

0.09 (0.10%)

AVGO

Broadcom

$276.39

-4.42 (-1.57%)

MRVL

Marvell

$19.65

0.05 (0.26%)

MU

Micron

$42.53

1.01 (2.43%)

QCOM

Qualcomm

$53.12

0.77 (1.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 07

    Mar

  • 07

    Mar

  • 07

    Mar

  • 12

    Mar

  • 13

    Mar

  • 14

    Mar

  • 14

    Mar

  • 20

    Mar

  • 25

    Mar

  • 26

    Mar

  • 09

    Apr

  • 28

    May

ETFC

E-Trade

$48.89

0.65 (1.35%)

09:25
02/23/19
02/23
09:25
02/23/19
09:25
Conference/Events
E-Trade to hold Education Day »

Education Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

CAT

Caterpillar

$138.77

-0.08 (-0.06%)

, XRX

Xerox

$31.50

0.16 (0.51%)

08:29
02/23/19
02/23
08:29
02/23/19
08:29
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

CAT

Caterpillar

$138.77

-0.08 (-0.06%)

XRX

Xerox

$31.50

0.16 (0.51%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$14.81

0.02 (0.14%)

F

Ford

$8.71

(0.00%)

GM

General Motors

$39.98

0.35 (0.88%)

HMC

Honda

$28.17

0.43 (1.55%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$121.84

0.66 (0.54%)

VLKAY

Volkswagen

$0.00

(0.00%)

NYT

New York Times

$31.51

-0.62 (-1.93%)

LUV

Southwest

$53.62

-0.69 (-1.27%)

VZ

Verizon

$56.95

0.81 (1.44%)

TMUS

T-Mobile

$73.17

-0.09 (-0.12%)

T

AT&T

$31.15

0.32 (1.04%)

NOK

Nokia

$6.21

0.06 (0.98%)

ERIC

Ericsson

$9.51

0.285 (3.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 28

    Feb

  • 03

    Mar

  • 03

    Mar

  • 04

    Mar

  • 11

    Mar

  • 13

    Mar

  • 20

    Mar

  • 27

    Mar

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

AIMT

Aimmune

$23.70

0.73 (3.18%)

, AZN

AstraZeneca

$40.95

0.515 (1.27%)

04:55
02/23/19
02/23
04:55
02/23/19
04:55
Conference/Events
The American Academy of Asthma, Allergy & Immunology to hold annual meeting »

AAAAI Annual Meeting 2019…

AIMT

Aimmune

$23.70

0.73 (3.18%)

AZN

AstraZeneca

$40.95

0.515 (1.27%)

TEVA

Teva

$17.28

0.03 (0.17%)

NVS

Novartis

$90.77

0.26 (0.29%)

DNA

Bought by RHHBY

$0.00

(0.00%)

SHPG

Shire

$0.00

(0.00%)

REGN

Regeneron

$422.43

3.77 (0.90%)

SNY

Sanofi

$41.20

-0.13 (-0.31%)

ALK

Alaska Air

$62.35

-0.48 (-0.76%)

ABT

Abbott

$76.40

1.26 (1.68%)

CVS

CVS Health

$62.00

-0.33 (-0.53%)

KALV

KalVista

$20.74

-0.04 (-0.19%)

BCRX

BioCryst

$8.99

0.32 (3.69%)

OPTN

Optinose

$7.31

0.02 (0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 04

    Mar

  • 04

    Mar

  • 04

    Mar

  • 07

    Mar

  • 11

    Mar

  • 11

    Mar

  • 12

    Mar

  • 18

    Mar

  • 19

    Mar

  • 22

    Mar

  • 28

    Apr

  • 13

    May

  • 18

    May

ETFC

E-Trade

$48.89

0.65 (1.35%)

04:55
02/23/19
02/23
04:55
02/23/19
04:55
Conference/Events
E-Trade to hold Education Day »

Education Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

TEX

Terex

$35.29

-0.3 (-0.84%)

19:01
02/22/19
02/22
19:01
02/22/19
19:01
Hot Stocks
Terex to sell Demag Mobile Cranes business to Tadano for $215M enterprise value »

Terex announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

CZR

Caesars

$9.05

-0.37 (-3.93%)

18:34
02/22/19
02/22
18:34
02/22/19
18:34
Hot Stocks
Canyon Partners: Caesars shareholders' value best served by open sale process »

Canyon Partners issued…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ERJ

Embraer

$20.85

0.17 (0.82%)

, BA

Boeing

$424.05

6.57 (1.57%)

18:11
02/22/19
02/22
18:11
02/22/19
18:11
Periodicals
Brazilian judge suspends Embraer-Boeing deal talks, Reuters reports »

A Brazilian judge…

ERJ

Embraer

$20.85

0.17 (0.82%)

BA

Boeing

$424.05

6.57 (1.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 11

    Mar

  • 14

    Mar

  • 28

    May

BXG

Bluegreen Vacations

$14.47

0.55 (3.95%)

18:02
02/22/19
02/22
18:02
02/22/19
18:02
Earnings
Bluegreen Vacations reports Q4 EPS 27c, consensus 24c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

SM

SM Energy

$16.88

-0.13 (-0.76%)

17:57
02/22/19
02/22
17:57
02/22/19
17:57
Recommendations
SM Energy analyst commentary at MUFG »

SM Energy's higher…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AN

AutoNation

$37.22

-1.15 (-3.00%)

17:47
02/22/19
02/22
17:47
02/22/19
17:47
Syndicate
Breaking Syndicate news story on AutoNation »

AutoNation files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 27

    Feb

TSLA

Tesla

$294.60

3.42 (1.17%)

, NSANY

Nissan

$0.00

(0.00%)

17:42
02/22/19
02/22
17:42
02/22/19
17:42
Periodicals
Tesla's Model 3 was the highest-selling EV globally in 2018, Verge reports »

Tesla's (TSLA) Model…

TSLA

Tesla

$294.60

3.42 (1.17%)

NSANY

Nissan

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 18

    Mar

  • 19

    Mar

FSFG

First Savings Financial Group

$51.33

0.22 (0.43%)

17:31
02/22/19
02/22
17:31
02/22/19
17:31
Hot Stocks
First Savings Financial raises quarterly dividend to 16c per share from 15c »

The dividend will be paid…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$110.97

1.5 (1.37%)

17:31
02/22/19
02/22
17:31
02/22/19
17:31
Periodicals
Employees demand Microsoft cancel $480M U.S. Army contract, Reuters says »

Several Microsoft workers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 01

    Mar

  • 03

    Mar

  • 04

    Mar

  • 06

    Mar

  • 07

    Mar

  • 18

    Mar

ENT

Global Eagle

$2.66

(0.00%)

17:23
02/22/19
02/22
17:23
02/22/19
17:23
Hot Stocks
Global Eagle to cut workforce by roughly 15% »

As previously disclosed,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

17:15
02/22/19
02/22
17:15
02/22/19
17:15
General news
Breaking General news story  »

New York Federal Reserve…

NOC

Northrop Grumman

$288.84

2.54 (0.89%)

17:13
02/22/19
02/22
17:13
02/22/19
17:13
Hot Stocks
Northrop Grumman exec Kalan sells 4,312 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LYB

LyondellBasell

$89.14

0.63 (0.71%)

17:07
02/22/19
02/22
17:07
02/22/19
17:07
Syndicate
Breaking Syndicate news story on LyondellBasell »

LyondellBasell files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCCO

Technical Comm Corp

$2.76

0.17 (6.56%)

17:06
02/22/19
02/22
17:06
02/22/19
17:06
Hot Stocks
Technical Comm Corp to submit plan to regain compliance with Nasdaq by March 4 »

Technical Comm Corp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.